Clinical factors associated with increase in serum transthyretin levels at 1-year with tafamidis in wild-type transthyretin amyloid cardiomyopathy

Scritto il 30/08/2026
da Koji Yoshie

No abstract

J Cardiol. 2026 Aug 31:S0914-5087(26)00160-7. doi: 10.1016/j.jjcc.2026.07.022. Online ahead of print.

NO ABSTRACT

PMID:42669580 | DOI:10.1016/j.jjcc.2026.07.022